LEO Pharma Inc. is a wholly-owned subsidiary of the LEO Foundation of Denmark. The Foundation is an independent Research Foundation specializing in dermatology, hemostasis and inflammation. The dermatology portfolio includes topical Fucidin^® the most often prescribed topical antibiotic in Canada, Dovobet^® the most often prescribed brand for the management of body plaque psoriasis, as well as Fucidin^® H for mild to moderate atopic dermatitis. The newest brand to join the LEO^® family is Xamiol^® gel for scalp psoriasis.

The LEO Foundation prides itself in its ability to generate the highest quality of research to support its therapies. This has been accomplished through an active network of world-class researchers, including more than 200 dermatologists in Canada.

^®registered trademark of LEO Pharma A/S used under license by LEO Pharma Inc., Thornhill, Ontario

Click here to close this window
and return to the Dermatology Update Sponsors Page.